Senda drives 3 programs toward clinic with bumped-up $98M series B

Flagship Pioneering united its “intersystems biology” efforts under one roof last fall, and, now, that company is gearing up for human trials. With a $55 million boost, Senda Biosciences will push three programs into the clinic in 2022, including treatments for chronic kidney disease and metabolic diseases as well as an asset aimed at making checkpoint inhibitors work for more people.

Scroll Up
error: Content is protected !!